What's happened
The FDA has approved Lipfendra, Merck’s oral PCSK9 inhibitor, to lower LDL cholesterol in patients on statins. Trials show ~55-60% LDL reductions; the pill will be sold at about $315/month and must be taken on an empty stomach. Analysts see potential peak sales in the billions as injectable rivals face competition and access barriers.
What's behind the headline?
In-Depth Look
- Lipfendra’s approval signals a shift in cholesterol care from injections to an oral option, potentially broadening access for patients deterred by injections.
- The price point and daily dosing raise questions about insurance coverage and real-world adherence compared with injectable therapies.
- The strategic timing intersects with ongoing, high-stakes competition among PCSK9 inhibitors and shifting guidelines for LDL targets.
- The move could spur upgrades in primary-care prescribing, hastening broader adoption beyond specialist clinics.
- A key debate is whether oral access will translate into meaningful reductions in cardiovascular events, beyond LDL reductions shown in trials.
How we got here
Lipfendra, or enlicitide, marks the first oral PCSK9 inhibitor approved to supplement statin therapy for high LDL cholesterol, including familial hypercholesterolemia. It expands Merck’s cholesterol-lowering portfolio and targets patients reluctant to injections. The approval follows two late-stage trials demonstrating substantial LDL reductions and comparable safety to placebo.
Our analysis
AP News: Lipfendra approval notes LDL reductions of ~55-59% with solid safety. CNBC: Lipfendra positioned as first oral PCSK9 inhibitor, with market momentum. Bloomberg: FDA approval announced; Lipfendra may reshape cholesterol treatment landscape. New York Post: Highlights pricing at $315/month and near-term availability.
Go deeper
- How will insurers handle Lipfendra coverage relative to injectables?
- What are the anticipated timelines for real-world cardiovascular outcomes data?
- Will primary care adopt Lipfendra widely or will endocrinology/specialists remain gatekeepers?
More on these topics
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.
-
Amgen - Biotechnology company
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
-
Robert Wood Johnson Foundation - Health care company
The Robert Wood Johnson Foundation is the United States' largest philanthropy focused solely on health; it is based in Princeton, New Jersey. The foundation's goal, through the use of grants, is "to improve the health and health care of all Americans." Th
-
Howard Hughes Medical Institute - Foundation
The Howard Hughes Medical Institute (HHMI) is an American non-profit medical research organization based in Chevy Chase, Maryland. It was founded in 1953, by Howard Hughes who was an American business magnate, investor, record-setting pilot, engineer...
-
New Jersey - US State
New Jersey is a state in the Mid-Atlantic region of the Northeastern United States. It is bordered on the north and east by the state of New York; on the east, southeast, and south by the Atlantic Ocean; on the west by the Delaware River and Pennsylvania;
-
Marty Makary - Surgeon
Martin Adel "Marty" Makary is a British-American surgeon, professor, and author. He practices surgical oncology and gastrointestinal laparoscopic surgery at the Johns Hopkins Hospital, is Mark Ravitch Chair in Gastrointestinal Surgery at Johns Hopkins Sch
-
Sanofi - Pharmaceutical company
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales.
-
American Heart Association - Nonprofit organization
The American Heart Association is a nonprofit organization in the United States that funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by ca
-
PCSK9 - Protein
Proprotein convertase subtilisin/kexin type 9 is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. It is the 9th member of the proprotein convertase family of proteins that activate other proteins. Similar genes are found across many species.